Lys Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$5M
- Investors
-
9
Lys Therapeutics General Information
Description
Developer of biotherapies designed to treat patients suffering from neurovascular or neurodegenerative disorders. The company's drugs are based on the monoclonal antibody, one protease called tissue plasminogen activator (tPA) that triggers off-target toxicity through hyperactivation of both vascular and neuronal NMDA receptors (NMDAr), enabling healthcare providers to counteract neuroinflammation to tackle neurodegeneration.
Contact Information
Website
www.lystherapeutics.comCorporate Office
- 56 rue Saint-Jean-De-Dieu
- 69007 Lyon
- France
Corporate Office
- 56 rue Saint-Jean-De-Dieu
- 69007 Lyon
- France
Lys Therapeutics Timeline
Lys Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Grant | 22-Sep-2025 | $5M | Completed | Clinical Trials - General | ||
| 10. Grant | 24-Sep-2024 | Completed | Clinical Trials - General | |||
| 9. Early Stage VC | 01-Jan-2024 | Completed | Clinical Trials - General | |||
| 8. Accelerator/Incubator | 01-Jan-2024 | Completed | Clinical Trials - General | |||
| 7. Grant | 14-Nov-2023 | Completed | Clinical Trials - General | |||
| 6. Grant | 15-Mar-2023 | Completed | Clinical Trials - General | |||
| 5. Seed Round | 20-Nov-2022 | Completed | Clinical Trials - General | |||
| 4. Grant | 15-Oct-2021 | Completed | Clinical Trials - General | |||
| 3. Seed Round | 01-Jan-2021 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup |
Lys Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Lys Therapeutics Patents
Lys Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260226177-A1 | Antibodies for treating neurological and neurovascular disorders | Pending | 05-Aug-2024 | ||
| WO-2026033259-A1 | Antibodies for treating neurological and neurovascular disorders | Pending | 05-Aug-2024 |
Lys Therapeutics Signals
Lys Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Iventure (Grenoble) | Accelerator/Incubator | |||
| Normandie Participations | Venture Capital | Minority | ||
| Michael J. Fox Foundation | Limited Partner | |||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| Health Technology Holding | Venture Capital | Minority |
Lys Therapeutics FAQs
-
When was Lys Therapeutics founded?
Lys Therapeutics was founded in 2021.
-
Where is Lys Therapeutics headquartered?
Lys Therapeutics is headquartered in Lyon, France.
-
What is the size of Lys Therapeutics?
Lys Therapeutics has 15 total employees.
-
What industry is Lys Therapeutics in?
Lys Therapeutics’s primary industry is Drug Discovery.
-
Is Lys Therapeutics a private or public company?
Lys Therapeutics is a Private company.
-
What is Lys Therapeutics’s current revenue?
The current revenue for Lys Therapeutics is .
-
How much funding has Lys Therapeutics raised over time?
Lys Therapeutics has raised $5.53M.
-
Who are Lys Therapeutics’s investors?
Iventure (Grenoble), Normandie Participations, Michael J. Fox Foundation, Bpifrance, and Health Technology Holding are 5 of 9 investors who have invested in Lys Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process